GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Shanghai RAAS Blood Products Co Ltd (SZSE:002252) » Definitions » Piotroski F-Score

Shanghai RAAS Blood Products Co (SZSE:002252) Piotroski F-Score : 6 (As of May. 08, 2024)


View and export this data going back to 2008. Start your Free Trial

What is Shanghai RAAS Blood Products Co Piotroski F-Score?

The zones of discrimination were as such:

Good or high score = 7, 8, 9
Bad or low score = 0, 1, 2, 3

Shanghai RAAS Blood Products Co has an F-score of 6 indicating the company's financial situation is typical for a stable company.

The historical rank and industry rank for Shanghai RAAS Blood Products Co's Piotroski F-Score or its related term are showing as below:

SZSE:002252' s Piotroski F-Score Range Over the Past 10 Years
Min: 2   Med: 5   Max: 8
Current: 6

During the past 13 years, the highest Piotroski F-Score of Shanghai RAAS Blood Products Co was 8. The lowest was 2. And the median was 5.


Shanghai RAAS Blood Products Co Piotroski F-Score Historical Data

The historical data trend for Shanghai RAAS Blood Products Co's Piotroski F-Score can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Shanghai RAAS Blood Products Co Piotroski F-Score Chart

Shanghai RAAS Blood Products Co Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Piotroski F-Score
Get a 7-Day Free Trial Premium Member Only Premium Member Only 7.00 6.00 2.00 6.00 6.00

Shanghai RAAS Blood Products Co Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Piotroski F-Score Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 7.00 6.00 7.00 6.00 6.00

Competitive Comparison of Shanghai RAAS Blood Products Co's Piotroski F-Score

For the Biotechnology subindustry, Shanghai RAAS Blood Products Co's Piotroski F-Score, along with its competitors' market caps and Piotroski F-Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Shanghai RAAS Blood Products Co's Piotroski F-Score Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Shanghai RAAS Blood Products Co's Piotroski F-Score distribution charts can be found below:

* The bar in red indicates where Shanghai RAAS Blood Products Co's Piotroski F-Score falls into.


How is the Piotroski F-Score calculated?

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

This Year (Mar24) TTM:Last Year (Mar23) TTM:
Net Income was 520.431 + 548.606 + -8.128 + 756.816 = ¥1,818 Mil.
Cash Flow from Operations was 362.929 + 507.008 + 337.432 + 750.872 = ¥1,958 Mil.
Revenue was 1837.587 + 2034.745 + 2028.588 + 2056.306 = ¥7,957 Mil.
Gross Profit was 757.703 + 828.188 + 760.56 + 814.862 = ¥3,161 Mil.
Average Total Assets from the begining of this year (Mar23)
to the end of this year (Mar24) was
(31008.256 + 32173.321 + 31912.46 + 31928.454 + 32776.666) / 5 = ¥31959.8314 Mil.
Total Assets at the begining of this year (Mar23) was ¥31,008 Mil.
Long-Term Debt & Capital Lease Obligation was ¥2 Mil.
Total Current Assets was ¥9,256 Mil.
Total Current Liabilities was ¥2,283 Mil.
Net Income was 513.039 + 542.74 + 276.278 + 718.568 = ¥2,051 Mil.

Revenue was 1608.025 + 1658.02 + 1615.655 + 2063.039 = ¥6,945 Mil.
Gross Profit was 699.732 + 764.807 + 665.19 + 902.188 = ¥3,032 Mil.
Average Total Assets from the begining of last year (Mar22)
to the end of last year (Mar23) was
(27698.268 + 28998.625 + 30228.237 + 30457.959 + 31008.256) / 5 = ¥29678.269 Mil.
Total Assets at the begining of last year (Mar22) was ¥27,698 Mil.
Long-Term Debt & Capital Lease Obligation was ¥2 Mil.
Total Current Assets was ¥8,654 Mil.
Total Current Liabilities was ¥1,649 Mil.

*Note: If the latest quarterly/semi-annual/annual total assets data is 0, then we will use previous quarterly/semi-annual/annual data for all the items in the balance sheet.

Profitability

Question 1. Return on Assets (ROA)

Net income before extraordinary items for the year divided by Total Assets at the beginning of the year.

Score 1 if positive, 0 if negative.

Shanghai RAAS Blood Products Co's current Net Income (TTM) was 1,818. ==> Positive ==> Score 1.

Question 2. Cash Flow Return on Assets (CFROA)

Net cash flow from operating activities (operating cash flow) divided by Total Assets at the beginning of the year.

Score 1 if positive, 0 if negative.

Shanghai RAAS Blood Products Co's current Cash Flow from Operations (TTM) was 1,958. ==> Positive ==> Score 1.

Question 3. Change in Return on Assets

Compare this year's return on assets (1) to last year's return on assets.

Score 1 if it's higher, 0 if it's lower.

ROA (This Year)=Net Income/Total Assets (Mar23)
=1817.725/31008.256
=0.05862068

ROA (Last Year)=Net Income/Total Assets (Mar22)
=2050.625/27698.268
=0.07403441

Shanghai RAAS Blood Products Co's return on assets of this year was 0.05862068. Shanghai RAAS Blood Products Co's return on assets of last year was 0.07403441. ==> Last year is higher ==> Score 0.

Question 4. Quality of Earnings (Accrual)

Compare Cash flow return on assets (2) to return on assets (1)

Score 1 if CFROA > ROA, 0 if CFROA <= ROA.

Shanghai RAAS Blood Products Co's current Net Income (TTM) was 1,818. Shanghai RAAS Blood Products Co's current Cash Flow from Operations (TTM) was 1,958. ==> 1,958 > 1,818 ==> CFROA > ROA ==> Score 1.

Funding

Question 5. Change in Gearing or Leverage

Compare this year's gearing (long-term debt divided by average total assets) to last year's gearing.

Score 0 if this year's gearing is higher, 1 otherwise.

Gearing (This Year: Mar24)=Long-Term Debt & Capital Lease Obligation/Average Total Assets from Mar23 to Mar24
=1.51/31959.8314
=4.725E-5

Gearing (Last Year: Mar23)=Long-Term Debt & Capital Lease Obligation/Average Total Assets from Mar22 to Mar23
=1.678/29678.269
=5.654E-5

Shanghai RAAS Blood Products Co's gearing of this year was 4.725E-5. Shanghai RAAS Blood Products Co's gearing of last year was 5.654E-5. ==> This year is lower or equal to last year. ==> Score 1.

Question 6. Change in Working Capital (Liquidity)

Compare this year's current ratio (current assets divided by current liabilities) to last year's current ratio.

Score 1 if this year's current ratio is higher, 0 if it's lower

Current Ratio (This Year: Mar24)=Total Current Assets/Total Current Liabilities
=9256.011/2283.179
=4.05400146

Current Ratio (Last Year: Mar23)=Total Current Assets/Total Current Liabilities
=8653.865/1648.696
=5.2489149

Shanghai RAAS Blood Products Co's current ratio of this year was 4.05400146. Shanghai RAAS Blood Products Co's current ratio of last year was 5.2489149. ==> Last year's current ratio is higher ==> Score 0.

Question 7. Change in Shares in Issue

Compare the number of shares in issue this year, to the number in issue last year.

Score 0 if there is larger number of shares in issue this year, 1 otherwise.

Shanghai RAAS Blood Products Co's number of shares in issue this year was 6638.738. Shanghai RAAS Blood Products Co's number of shares in issue last year was 6715.59. ==> There is smaller number of shares in issue this year, or the same. ==> Score 1.

Efficiency

Question 8. Change in Gross Margin

Compare this year's gross margin (Gross Profit divided by sales) to last year's.

Score 1 if this year's gross margin is higher, 0 if it's lower.

Gross Margin (This Year: TTM)=Gross Profit/Revenue
=3161.313/7957.226
=0.39728833

Gross Margin (Last Year: TTM)=Gross Profit/Revenue
=3031.917/6944.739
=0.43657753

Shanghai RAAS Blood Products Co's gross margin of this year was 0.39728833. Shanghai RAAS Blood Products Co's gross margin of last year was 0.43657753. ==> Last year's gross margin is higher ==> Score 0.

Question 9. Change in asset turnover

Compare this year's asset turnover (total sales for the year divided by total assets at the beginning of the year) to last year's asset turnover ratio.

Score 1 if this year's asset turnover ratio is higher, 0 if it's lower

Asset Turnover (This Year)=Revenue/Total Assets at the Beginning of This Year (Mar23)
=7957.226/31008.256
=0.25661637

Asset Turnover (Last Year)=Revenue/Total Assets at the Beginning of Last Year (Mar22)
=6944.739/27698.268
=0.25072828

Shanghai RAAS Blood Products Co's asset turnover of this year was 0.25661637. Shanghai RAAS Blood Products Co's asset turnover of last year was 0.25072828. ==> This year's asset turnover is higher. ==> Score 1.

Evaluation

Piotroski F-Score= Que. 1+ Que. 2+ Que. 3+Que. 4+Que. 5+Que. 6+Que. 7+Que. 8+Que. 9
=1+1+0+1+1+0+1+0+1
=6

Good or high score = 7, 8, 9
Bad or low score = 0, 1, 2, 3

Shanghai RAAS Blood Products Co has an F-score of 6 indicating the company's financial situation is typical for a stable company.

Shanghai RAAS Blood Products Co  (SZSE:002252) Piotroski F-Score Explanation

The developer of the system is Joseph D. Piotroski is relatively unknown accounting professor who shuns publicity and rarely gives interviews.

He graduated from the University of Illinois with a B.S. in accounting in 1989, received an M.B.A. from Indiana University in 1994. Five years later, in 1999, after earning a Ph.D. in accounting from the University of Michigan, he became an associate professor of accounting at the University of Chicago.

In 2000, he wrote a research paper called "Value Investing: The Use of Historical Financial Statement Information to Separate Winners from Losers" (pdf).

He wanted to see if he can develop a system (using a simple nine-point scoring system) that can increase the returns of a strategy of investing in low price to book (referred to in the paper as high book to market) value companies.

What he found was something that exceeded his most optimistic expectations.

Buying only those companies that scored highest (8 or 9) on his nine-point scale, or F-Score as he called it, over the 20 year period from 1976 to 1996 led to an average out-performance over the market of 13.4%.

Even more impressive were the results of a strategy of investing in the highest F-Score companies (8 or 9) and shorting companies with the lowest F-Score (0 or 1).

Over the same period from 1976 to 1996 (20 years) this strategy led to an average yearly return of 23%, substantially outperforming the average S&P 500 index return of 15.83% over the same period.


Shanghai RAAS Blood Products Co Piotroski F-Score Related Terms

Thank you for viewing the detailed overview of Shanghai RAAS Blood Products Co's Piotroski F-Score provided by GuruFocus.com. Please click on the following links to see related term pages.


Shanghai RAAS Blood Products Co (SZSE:002252) Business Description

Traded in Other Exchanges
N/A
Address
No. 2009, Wangyuan Road, Fengxian District, Shanghai, CHN, 201401
Shanghai RAAS Blood Products Co Ltd is a blood products manufacturer in China that has high comprehensive utilization of plasma raw material and a range of products with different specifications. It is engaged in the research, development, and manufacture of blood products and plasma-derived medical products. The company's products include albumin, coagulation factors, and others.

Shanghai RAAS Blood Products Co (SZSE:002252) Headlines

No Headlines